Navigation Links
Comparison of Biopharmaceutical Industry Between China and India 2013
Date:4/18/2013

DUBLIN, April 18, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Comparison of Biopharmaceutical Industry between China and India 2013" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The report, Comparison of Biopharmaceutical Industry between China and India, has revealed the relative competencies of the biopharmaceutical industry in these two countries, including their current capabilities and capacities in biologic drug R&D and manufacturing.

It is the first time in the history that the biopharmaceutical industries in both China and India are completely analyzed and compared. The report thus presents a complete picture to multinational companies of which country can do what at present and which one between China and India is better in which areas and thus best suitable for what types of collaboration, etc. Moreover, it provides clear insights of the future development directions of the biopharmaceutical industry in each of these two countries.

The report is thus a must-read book to all global pharmaceutical, biopharmaceutical and financial investment companies that are interested to have a best position in either one of these two countries. It is also a valuable reference book to drug regulatory agencies and other government agencies that are involved in strategic planning for development of biopharmaceutical industry in their own countries.

Key Features of the Report

- The report is designed to help professionals in the global biopharmaceutical industry better understand the current development states, technical capabilities and relative competencies of China and India in biologic drug R&D and manufacturing, as well as the future growth potentials of their biopharmaceutical industries.

- The report thus first analyzed and compared both in detail and in depth the current states of the biopharmaceutical industry in both China and India. It is the first time that the report revealed the similarities and differences between China and India in biopharmaceutical industry, their strengths and weaknesses in this industry, and the advantages and disadvantages each country possesses for future development of this nascent but dynamically growing industry.

- The report also analyzed and compared the current structural compositions of the biopharmaceutical industry in China and India, and the biopharmaceutical product scope and type each country is currently able to produce. It thus revealed the current manufacturing capabilities and capacities of the Chinese and Indian biopharmaceutical industries.

- Meanwhile, the report also analyzed and compared the novel biologic drugs and biosimilar products currently under development in those major biopharma companies in each country. It thus revealed the current capabilities of Chinese and Indian biopharma companies in biologic drug R&D.

- More importantly, the report also analyzed the opportunities and challenges in the foreseeable future facing Chinese and Indian biopharma companies in the competitive global biopharmaceutical market, as well as the actions and strategies each country is currently taking to enhance their competitiveness.

- The in-depth analysis and in-detail comparison the report has conducted have provided a clear and complete picture of the current relative competiveness of China and India in the global biopharmaceutical industry. It thus greatly helps global pharmaceutical and biopharmaceutical companies to best gauge the possible collaboration and partnership opportunities with local counterparts in these two countries.

- The report also analyzed in detail the current market sizes, past growth histories and the future growth potentials of the biopharmaceutical market in each country, including the submarket sectors of therapeutic proteins, vaccines and therapeutic mAbs. It has thus revealed both the attractiveness of the local biopharmaceutical markets and their differences. The report will thus greatly facilitate the global pharmaceutical and biopharmaceutical companies to formulate their best market strategies in these two important yet still dynamically growing markets.

Key Topics Covered:

Executive Summary

  • Attractions of fast growing Chinese and Indian biopharmaceutical markets
  • Comparison of biopharmaceutical manufacturing between China and India
  • Comparison of biopharmaceutical R&D between China and India
  • Outlook of future growth potentials of biopharmaceutical industry in China and India

Chapter One - Attractions of Fast Growing Chinese and Indian Biopharmaceutical Markets

Chapter Two - Comparison of Biopharmaceutical Manufacturing between China and India

Chapter Three - Comparison of Biopharmaceutical R&D between China and India

Chapter Four - Outlook of Future Growth Potentials of Biopharmaceutical Industry in China and India

Index I. Chinese Companies Cited in the Report

Index II. Indian Companies Cited in the Report


For more information visit Comparison of Biopharmaceutical Industry between China and India 2013

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
2. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
6. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
7. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
8. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
9. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
11. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  The Welch Foundation, ... for basic research, today announced that Drs. Neal ... are the 2017 recipients of the Norman Hackerman ... recognized as ,rising stars, having contributed significant scientific discoveries ... first time in the 15 years of the Hackerman ...
(Date:3/1/2017)... , Mar 01, 2017 Research and ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... 2016, provides drug pricing data and benchmarks in the global Acute ... clinical attributes of your competitor drugs and find out how the ...
(Date:3/1/2017)... stesso sistema sara, visibile nello stand a ECR, il Congresso Europeo di Radiologia ... la settima unità MROpen in Gran Bretagna, la prima in Galles. Il sistema ... Cardiff. ESC attualmente gestisce altri due sistemi di risonanza magnetica MROpen a Londra ... ... The open MRI scanner - ...
Breaking Medicine Technology:
(Date:3/1/2017)... MA (PRWEB) , ... March 01, 2017 , ... ... Americans, while increasing access to the Supplemental Nutrition Assistance Program (SNAP) can reduce ... in a special issue of the American Journal of Preventive Medicine . ...
(Date:3/1/2017)... ... 01, 2017 , ... On January 27, 2017, Laffey, Bucci & Kent together ... lawsuit in the Circuit Court of Kanawha County, West Virginia. The lawsuit was filed ... initials. See L.B. and T.B. v. Seventh-Day Adventist Church et al. Case #: 17-C-146. ...
(Date:3/1/2017)... Sandy, Utah (PRWEB) , ... March 01, 2017 ... ... made the pledge to help increase colorectal cancer screening rates by supporting the ... for Disease Control and Prevention (CDC) and the National Colorectal Cancer Roundtable (an ...
(Date:3/1/2017)... ... ... “McFarnia”: a suspenseful tale of a father who vanishes without a trace and his ... the creation of published author Tony Pierzchala, a former Army man, steel worker and ... Transport for Christ at a truck stop in the Greensboro area. , Published ...
(Date:3/1/2017)... ... March 01, 2017 , ... Adherence Compliance, ... its Cannabis Compliance Program for Regulatory Agencies. The regulatory agency program is the ... with internal or outsourced compliance program options, as well as an app for ...
Breaking Medicine News(10 mins):